Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Vise andre og tillknytning
2018 (engelsk)Inngår i: Molecular Systems Biology, ISSN 1744-4292, E-ISSN 1744-4292, Vol. 14, nr 3, artikkel-id e7858Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Novel therapies are undergoing clinical trials, for example, the Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for the treatment of therapy-resistant melanomas. Unfortunately, our data show that this combination elicits a heterogeneous response in a panel of melanoma cell lines including PDX-derived models. We sought to understand the mechanisms underlying the differential responses and suggest a patient stratification strategy. Thermal proteome profiling (TPP) identified the protein targets of XL888 in a pair of sensitive and unresponsive cell lines. Unbiased proteomics and phosphoproteomics analyses identified CDK2 as a driver of resistance to both BRAF and Hsp90 inhibitors and its expression is regulated by the transcription factor MITF upon XL888 treatment. The CDK2 inhibitor, dinaciclib, attenuated resistance to both classes of inhibitors and combinations thereof. Notably, we found that MITF expression correlates with CDK2 upregulation in patients; thus, dinaciclib would warrant consideration for treatment of patients unresponsive to BRAF-MEK and/or Hsp90 inhibitors and/or harboring MITF amplification/overexpression. 

sted, utgiver, år, opplag, sider
Blackwell Publishing Ltd , 2018. Vol. 14, nr 3, artikkel-id e7858
Emneord [en]
CDK2, Hsp90 and BRAF inhibitors, melanoma, MITF, proteomics
HSV kategori
Identifikatorer
URN: urn:nbn:se:kth:diva-227407DOI: 10.15252/msb.20177858ISI: 000429006500002Scopus ID: 2-s2.0-85044744573OAI: oai:DiVA.org:kth-227407DiVA, id: diva2:1210673
Merknad

Export Date: 9 May 2018; Article; Correspondence Address: Maddalo, G.; Science for Life Laboratory, School of Biotechnology, KTH Royal Institute of TechnologySweden; email: gianluca.maddalo@scilifelab.se; Funding details: IHC, Idaho Humanities Council; Funding details: 154202, Cancerfonden; Funding details: 5310-7132, O. E. och Edla Johanssons Vetenskapliga Stiftelse; Funding details: MTA, Mount Allison University; Funding text: We acknowledge Prof. Sonia Lain and Prof. David Lane and their groups for technical support and for granting us permission to access their Orbitrap Fusion. The cell line pairs M026.X1.CL and M026R.X1.CL, and M029.X1.CL and M029.R.X1.CL have been used according to the Material Transfer Agreement (MTA) for academic institutions V01 13 and V08 16, respectively. GM has been awarded grants from: O. E. och Edla Johanssons foundation (5310-7132); Swedish Cancer Society (Radiumhemmets; 154202); and Lars Hiertas Minne. The authors acknowledge the entire staff of the Protein Atlas Project for the IHC images. We acknowledge Prof. Janne Lehtiö and Rozbeh Jafari for support with TPP. QC 20180529

Tilgjengelig fra: 2018-05-29 Laget: 2018-05-29 Sist oppdatert: 2020-01-10bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstScopus

Personposter BETA

Uhlén, Mathias

Søk i DiVA

Av forfatter/redaktør
Edfors, FredrikUhlén, Mathias
Av organisasjonen
I samme tidsskrift
Molecular Systems Biology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 110 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf